A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

In just a few weeks, you will have a special opportunity to rediscover downtown La Grange and support a good cause.

Nearly half of women diagnosed with ovarian cancer are not receiving the genetic testing that could help guide treatment and improve outcomes, according to a new analysis from Ovarian Cancer Research ...

Mural Oncology’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...

The University of Pennsylvania has taken a novel approach to ensure that women with suspicious adnexal lesions are referred ...